1. Home
  2. ADPT vs BLND Comparison

ADPT vs BLND Comparison

Compare ADPT & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • BLND
  • Stock Information
  • Founded
  • ADPT 2009
  • BLND 2012
  • Country
  • ADPT United States
  • BLND United States
  • Employees
  • ADPT N/A
  • BLND N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • BLND EDP Services
  • Sector
  • ADPT Health Care
  • BLND Technology
  • Exchange
  • ADPT Nasdaq
  • BLND Nasdaq
  • Market Cap
  • ADPT 929.8M
  • BLND 959.7M
  • IPO Year
  • ADPT 2019
  • BLND 2021
  • Fundamental
  • Price
  • ADPT $6.81
  • BLND $3.61
  • Analyst Decision
  • ADPT Buy
  • BLND Buy
  • Analyst Count
  • ADPT 4
  • BLND 8
  • Target Price
  • ADPT $6.75
  • BLND $4.86
  • AVG Volume (30 Days)
  • ADPT 1.3M
  • BLND 3.7M
  • Earning Date
  • ADPT 02-12-2025
  • BLND 03-13-2025
  • Dividend Yield
  • ADPT N/A
  • BLND N/A
  • EPS Growth
  • ADPT N/A
  • BLND N/A
  • EPS
  • ADPT N/A
  • BLND N/A
  • Revenue
  • ADPT $177,282,000.00
  • BLND $156,715,000.00
  • Revenue This Year
  • ADPT $6.48
  • BLND $5.35
  • Revenue Next Year
  • ADPT $18.72
  • BLND $20.75
  • P/E Ratio
  • ADPT N/A
  • BLND N/A
  • Revenue Growth
  • ADPT N/A
  • BLND N/A
  • 52 Week Low
  • ADPT $2.28
  • BLND $2.08
  • 52 Week High
  • ADPT $7.46
  • BLND $5.53
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 54.92
  • BLND 35.81
  • Support Level
  • ADPT $5.98
  • BLND $3.23
  • Resistance Level
  • ADPT $7.28
  • BLND $3.75
  • Average True Range (ATR)
  • ADPT 0.54
  • BLND 0.23
  • MACD
  • ADPT -0.00
  • BLND -0.03
  • Stochastic Oscillator
  • ADPT 58.06
  • BLND 32.33

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

Share on Social Networks: